2 hours
Waters Corporation District Office
Starting at USD 0
Thu, 20 Nov, 2025 at 04:00 pm to 06:00 pm (GMT-08:00)
Waters Corporation District Office
3540 Howard Way, Costa Mesa, United States
Presentation 1 (15 Min)
Breaking the Bacterial Barrier: Enhanced Targeted Therapy on the Lipopolysaccharide of Pseudomonas aeruginosa Using a Phage-Antibiotic Cocktail
Presented by
Ms. Driti Rajkumar
Microbiology & Immunology Research Intern
Department of Microbiology and Immunology,
University of California, Irvine
Abstract: Antibiotic resistance has become a global crisis, demanding innovative solutions beyond traditional drugs. Phage therapy—using viruses that target specific bacteria—offers a promising alternative due to its precision, biofilm-degrading ability, and low toxicity. This study focused on Pseudomonas aeruginosa, a multidrug-resistant pathogen responsible for hospital and cystic fibrosis infections. We investigated the synergy between bacteriophage OCP-2 (isolated from North Ohio sewage) and aminoglycosides Gentamicin and Tobramycin. The phage-antibiotic combinations significantly inhibited bacterial growth in vitro. Sequence analysis of OCP-2 revealed tail proteins resembling depolymerases, supporting its capacity to break down polysaccharides. Both treatments targeted lipopolysaccharides to enhance bacterial eradication. Future work aims to re-engineer phages with multiple mechanisms of action to boost therapeutic potential. These results underscore phage-antibiotic synergy as a powerful strategy to combat antibiotic-resistant P. aeruginosa.
Presentation 2 (45 Min)
Qualification of Primary Container Closures
Presented By
Aryo Nikopour
Vice President
Global Pharma Market Segment
Nelson Labs (A Sotera Health Company)
Abstract: Ensuring the integrity and performance of primary container closure systems (CCS) is a critical element of pharmaceutical product quality, safety, and regulatory compliance. As global regulatory expectations evolve — including requirements from the FDA, EMA, USP <1207>, ISO 8871 series, and EP 3.2 guidelines — manufacturers are under increasing pressure to implement robust qualification programs that address both functional performance and chemical safety.
This presentation highlights the scientific and regulatory framework for qualification of primary container closures, emphasizing the following key areas:
· Extractables & Leachables (E&L) Studies
· Container Closure Integrity Testing (CCIT)
· Functional & Mechanical Qualification
· Regulatory Expectations & Industry Trends
By combining scientific rigor with a risk-based, patient-centric approach, the presentation outlines best practices for developing a comprehensive qualification strategy that supports global submissions, mitigates compliance risk, and ensures that primary container closure systems perform reliably throughout a product’s lifecycle.
Also check out other Nonprofit events in Costa Mesa, Health & Wellness events in Costa Mesa.
Tickets for Main Presentation: Qualification of Primary Container Closures can be booked here.
| Ticket type | Ticket price |
|---|---|
| General Admission On-Site | 23 USD |
| General Admission On Site-AAPS Member | 18 USD |
| General Admission On-Site-Retired/Students | 7 USD |
| General Admission-Virtual | Free |
| Executive Committee/Speakers | Free |